Category Archives: Cf

Real Madrid host Getafe in an important fixture in La Liga's title race, with three points giving Zinadine Zidane's side a comfortable four point advantage on Barcelona with only five games left to play.

Since returning to action in June, Madrid have won all five of their league games which saw them leapfrog Barcelona at the top of the table.

However, Getafe have only managed one win since returning, cruising to a 2-1 victory against Real Sociedadin their most recent game - managing three draws and only one loss on their return.

Since returning to action, Karim Benzema has proved to be a valued piece to the Madrid puzzle, the Frenchman has scored three goals and assisted one in his last four appearances. Experienced defendersXabier Etxeitaand Djene Dakonam will be looking to nullify the threat of Benzema firing on all cylinders.

Last time the two sides met in January, Zidane's side emerged the victors in a 3-0 win away from home.

David Soria opened the scoring with an own goal to put Madrid ahead as he failed to collect a cross from FerlandMendy.

Toni Kroos delivered a cross whichRaphal Varane headed home on the 53rd minute to double the visitors lead.

Luka Modripiled more misery onto Getafein the 96th minute afterFederico Valverde'slaunched a late counter attack, whichModriended as he slotted home into an open goalwith ease.

Madrid are unbeaten in their previous four meetings with Getafe, winning four of those encounters and drawing one.

In positive news for Madrid,Mendy and Modri are available for selection after serving suspensions. Lucas Vazquez and Luka Jovic are two expected to miss the game through injury, Nacho may well be in for contention as he edges closer to fitness.

Jos Bordals' side managed to come through their clash against RealSociedad without any injuries ahead of tonight's big game.

Real Madrid XI: Courtois; Carvajal, Varane, Ramos, Mendy; Casemiro,Modric, Kroos; Hazard, Benzema,Vincius(4-3-3).

Getafe XI: Soria; Suarez, Etxeita, Djene, Olivera; Nyom, Maksimovic, Arambarri, Cucurella; Duro, Mata (4-4-2).

Zidaneis wary of his opposition, but insists his side will give his all in the race for the title:

"I am happy and proud of the players, because what they do is not easy.But we have six finals left and we must give the maximum.We're fine, but this doesn't mean anything.

"You don't know what will happen tomorrow.If we win it will not be definitive.We will not change.We just have to continue with our energy, which is good.Getafe is going to make it very complicated for us but we are going to try to win".

Read more:

Real Madrid vs Getafe CF preview: Madrid look to extend lead at top of the table to four points - VAVEL.com

Word on the street is there has been a recent increase in applications to become a FINRA regulated Funding Portal.

A funding portal is a relatively new entity created under the JOBS Act of 2012. Funding portals may raise capital under Regulation Crowdfunding, commonly referenced as Reg CF. A funding portal is a regulated entity and a bit like a broker-dealer lite as it must adhere to certain compliance rules as it hosts companies seeking capital that sell securities online.

Under current rules, an issuer may only raise $1.07 million under Reg CF in any one year a relatively anemic and arbitrary amount. The Securities and Exchange Commission (SEC) has proposed raising the funding cap to $5 million a move that may be fueling renewed interest in the securities exemption.

Currently, there are 54 FINRA regulated funding portals and 12 former funding portals that no longer operate (and several that have not paid their FINRA dues). Although there are a good number of these regulated investment platforms, the bulk of the Reg CF offerings are hosted on a handful of online capital formation platforms. As well, broker-dealers may issue securities under Reg CF and several former funding portals have let go of their funding portal designation to become broker-dealers.

So will we see an increase in new funding portals and affiliated securities offerings? Most likely yes, once the SEC moves the funding cap to a more reasonable amount.

Read the original post:

Reg CF Chatter: There are a Flood of New Funding Portal Applications - Crowdfund Insider

The orbisresearch.com has published Cystic Fibrosis (CF) Therapeutics market 2020 global trends and analysis report to its store

The Global Cystic Fibrosis (CF) Therapeutics market report is deep study of the present market dynamics. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecasted period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A significant development has been recorded by the market of Cystic Fibrosis (CF) Therapeutics, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A systematized methodology is used to make a Report on the Global Cystic Fibrosis (CF) Therapeutics market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports.

Request a pdf sample at

https://www.orbispharmareports.com/sample-request/19113

Browse the full report at

https://www.orbispharmareports.com/global-cystic-fibrosis-cf-therapeutics-market-2020-2026-report-by-type-applications-manufacturers-and-regional-overview/

Key Segmentation:

Key Players:Vertex PharmaceuticalsorporatedGileadAbbVie,Novartis AGF. Hoffmann-La Roche LtdAlaxiaMerck & Co.AIT (Advanced Inhalation Therapies)ALLERGANAstraZenecaTeva Pharmaceutical Industries LtdAlcresta

Types:Pancreatic enzyme supplementsMucolyticsBronchodilatorsCFTR modulators

Key Applications:Oral drugsInhaled drugs

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the Cystic Fibrosis (CF) Therapeutics market. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. For the analysis of market on the terms of research strategies, these techniques are helpful.

Have any inquiries on purchasing the report? If yes, then contact us @

https://www.orbispharmareports.com/enquiry-before-buying/19113

Potential consumers, market values, and the future scope for the Cystic Fibrosis (CF) Therapeutics market are explained thoroughly to the users in this report. The key players of Cystic Fibrosis (CF) Therapeutics industry, their product portfolio, market share, industry profiles is studied in this report. It is very important for the vendors to provide customers with new and improved product/ services in order to gain their loyalty. The study of various segments of the global market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Excerpt from:

Cystic Fibrosis (CF) Therapeutics Market Valuation 2020 | In Depth Analysis, Solution, Industry Influence Factors - Cole of Duty

Dr. Mona Hanna-Attisha

CRYSTAL FALLS The public is invited to join a Zoom meeting at 1 p.m. Thursday with two Crystal Falls Book Clubs as they connect with Dr. Mona Hanna-Attisha to discuss her book What the Eyes Dont See.

The book is her account of her discovery that Flints children were being poisoned by lead leaching into the citys drinking water. The book is Michigan Humanities choice for the 2019-20 Great Michigan Read, and the Crystal Falls District Library has partnered with Michigan Humanities to distribute free books as well as supporting educational materials at their library.

The library was given 30 books, reading guides, and bookmarks that have been circulating with patrons, the two book clubs in the area, and the library board. Evelyn Gathu, the director of the Crystal Falls Library contacted Hanna-Attisha about having a virtual book talk with the book clubs and patrons from the library.

Gathu said she was overjoyed when Hanna-Attisha herself responded by email positively. To get instructions to join the Zoom meeting, go to the librarys website: http://joomla.uproc.lib.mi.us/CrystalFalls/.

The Great Michigan Read aims to connect Michigan residents by deepening readers understanding of our state, our society, and our humanity. A statewide panel of teachers, librarians, community leaders and book lovers selects the Great Michigan Read every two years.

Shelly Hendrick Kasprzycki, Michigan Humanities president and CEO, said she hopes What the Eyes Dont See will encourage Michigan citizens statewide to read, discuss and learn from the book, and that it will increase opportunities for civil discourse on topics ranging from water quality and access to environmental injustice and the intersection of humanities and science.

Dr. Mona Hanna-Attishas willingness to fight for children and tirelessly advocate for change in and beyond Michigan will have readers cheering as she follows the science and her young patients experiences to uncover one of the states worst public health catastrophes, Kasprzycki said.

Hanna-Attisha is the founder and director of the Michigan State University and Hurley Childrens Hospital Pediatric Public Health Initiative, an innovative and model public health program in Flint.

Currently an associate professor of pediatrics and human development at the MSU College of Human Medicine, she has been named one of Time magazines 100 Most Influential People in the World for her role in uncovering the Flint water crisis and leading recovery efforts.

She was among the first to question if lead was leaching from the citys water pipes after an emergency manager switched the citys water supply to the Flint River in 2014. She also is committed to increasing literacy in Flint and elsewhere.

Hanna-Attisha said she was honored to have What the Eyes Dont See chosen for the 2019-20 Great Michigan Read, and said the concepts of place and history are critically important to her book.

From the resistance of the Flint sit-down strikers to the reign of demagogue Charles Coughlin, Michigans DNA is full of history some good and some bad and some shared and some hidden which we must understand in order to address our present-day challenges, she said. Like so many Michiganders, my story is an immigrant story. It was critical to share this part of the story in this memoir because it informs how I see the world and the work that I am privileged to do.

Copies of What the Eyes Dont See are available at the library for those who want to read the book. The Crystal Falls District Community Library is currently open for curbside service only. To get a copy of the book, email staff at cflib@uproc.lib.mi.us or call 906-875-4465.

The 2019-20 Great Michigan Read is presented by Michigan Humanities and supported by national, statewide, and local partners, including the National Endowment for the Humanities and The Meijer Foundation.

Today's breaking news and more in your inbox

Read more:

CF library to host Zoom meeting with doctor who discovered Flint water crisis | News, Sports, Jobs - Iron Mountain Daily News

Born with cystic fibrosis, Rob Law lost his sister to the disease, was told hed die young and never have kids and had his business idea dismissed as worthless on Dragons Den. Having just launched his memoir, he tells about defying the odds, following his passion and keeping fighting when the experts were telling him to quit.

Rob Law and his children daughter Ida, 6, and his two sons, Rafe, 3, and Kip, 1 Theyre my greatest achievement, says Law, who has just published his memoir.

AS A YOUNG man on the cusp of adulthood, Rob Law was told it wouldnt be possible for him to have children.

Law, now 43, has Cystic Fibrosis (CF), the progressive genetic condition that negatively impacts multiple body functions including breathing and digestion.

CF especially for men affects the reproductive system. It blocks tubes, says Law, who wasnt thinking much about babies when told in his early 20s hed be childless.

But the years went on and his priorities crystallised. I wanted financial security and I wanted to start a family. I love kids Im a big kid at heart. Fortunately, my partner, Kathryn, also wanted children and shed researched the medical interventions that had come on stream by then.

The couple embarked on a course of intracytoplasmic sperm injection (ICSI), used instead of standard IVF when sperm arent swimming well enough to fertilise eggs.

It was a challenging journey. We were successful in pregnancy but we had two miscarriages.

Rob Law Rob with sister Kate on a family holiday in Canada four months before she died from CF.

And then their fortunes turned, with Ida born in February 2014. Aged six now, the little girl has two brothers, Rafe, 3, and Kip, 1. Theyre my greatest achievement, says Law, who has just published his memoir.

In refusing to accept childlessness as his fate, Law was doing what he has always done from a young age defying the expected life trajectory that seemed laid out for him.

At 16 he lost his beloved twin sister Kate to CF. She was a very bubbly character, very into her books, whereas he was more outdoorsy. Like most twins, they communicated via our own gobbledegook. But CF took a stronger grip on Kate.

Her lungs got to where they were really causing her a lot of difficulty. She was put on a heart and lung transplant list and got a new pair of lungs 18 months before she passed but her body rejected them.

Hugely devastated and traumatised by her death, Law, who was born near Chester in the UK, realised he could well share Kates fate in just a few years medics said he couldnt expect to live into his 20s.

Rather than wallowing, I put CF behind a wall and chose life. In the months after her death, I decided life was to be lived and that mine could be short, so I wanted to get the most out of it.

Struggling with dyslexia at school, he took refuge in the arts and discovered product design. I was completely sold on it. I was very excited about designing consumer products I set out to do the best course I could.

In his second year studying Product Design at university looking for ideas so he could enter a national competition Law wandered into the luggage section of his local department store, noticed hard-moulded plastic suitcases that were on trend but were all black and boring and then drifted into the kids toy section. I was looking at the ride-on toys and remembering how my younger brother, Dave, enjoyed going round the garden on his ride-on tractor and it came to me.

Rob Law with daughter Ida as a baby. Rob was told he wouldn't be able to have children due to CF.

His idea was the Trunki, a colourful ride-on childs suitcase. But when he brought it on Dragons Den -BBC- in 2006, it was massively rejected judges said it wasnt a business opportunity and that the company hed set up was worthless. Id quit my job as a design consultant three weeks earlier. Sixteen hundred Trunkis had just arrived in the UK. Id just started trading, recalls Law, who says the humiliating experience is embedded on his mind.

When Peter Jones told me it was worthless, I just didnt understand the words coming out of his mouth. I had a brand and a product taken all the way to market, so it didnt sound worthless to me. I was kind of numb. I thought this was the death knell of the business.

It wasnt the Trunki went on to sell in the millions and to win awards and Law had a moment a few years ago when the constellation of his achievements really hit home.

We were going to my brothers wedding and on the long walk from gate to baggage check Ida was using her Trunki for the first time and really enjoying riding on it. It struck me: I was on a journey that I wasnt supposed to have, with a daughter I was told Id never have, on a product I was told was worthless, says the man who named his memoir (65 Roses and a Trunki) for his creation and for his condition: 65 Roses is how young children often get their tongues around cystic fibrosis.

Health-wise, Laws on lots of medication, as well as twice-daily physiotherapy for lung clearance. He decided many years ago rather than coasting to set himself fitness goals: to do a half-marathon a month, three and a half marathons a month, to do the 600-odd miles from Lands End to John OGroats. He caught the triathlon bug, competing at middle distance. With three kids now, I cant get that level of training. Ive recently focused on swimming. Last year I did a 6K swim.

HE COUNTS himself as one of the lucky ones. There are a lot worse off than me. The perspective that hes really quite fortunate permeates even the tough phases. In lockdown at home in Bristol with Kathryn and the kids, he knows hes extremely vulnerable to Covid-19 and has been told so by medics. But in life, as in lockdown, his habit is always to focus on the more short-term, on what he can control.

I shouldnt be leaving my front door, but I still get out in the evenings for a cycle or run when the kids are down. Weve got nice gardens, a good coffee machine Im grateful for those and for being able to spend more time with the children.

Read more:

Rob Law: How I defied the doctors - and Dragon's Den - Irish Examiner

In the 1970s, when Luke Peters and Sammie Read were diagnosed with CF, their parents were told if they made it to their teenage years they would have done well.

Now in their 40s, the friends are still living with the condition.

Treatment has come on leaps and bounds in the past four decades, with Sammie feeling the benefits of a new drug and Luke a year into his recovery following a double lung transplant.

This year, classed as clinically extremely vulnerable, they have had to shield from coronavirus, yet they remain positive.

When Luke was diagnosed aged 13 months his parents were told the outlook was pretty bleak, however he remained fit and well throughout his childhood. It was not until he started working in the aviation industry CF began to affect him.

However, he carried on through his first career, then went to law school to retrain in his late 20s and became a solicitor in the city.

But just before his 40th birthday he was advised to reduce his working hours as CF increasingly took its toll, before he was forced to stop working altogether.

I was fighting a losing battle and trying to work even part-time was putting too much stress on my body, said Luke.

I was a stay-at-home dad for a few years with my son and then my daughter (now aged nine and six). But throughout 2016 my lung function was down to 20 per cent and I was told I needed to get on the transplant list. If I didnt, I might not survive.

Luke was on the list from January 2017 until May 2019. In that time he had two false alarms, when he was telephoned in the middle of the night and travelled to hospital for an anxious wait to see if the lungs were viable.

It was a case of third time lucky when, on May 1 last year, he received the third early hours call. After travelling to Harefield Hospital, in London, for the transplant surgery Luke was unconscious for eight days spending his 47th birthday asleep and spent five weeks in hospital.

Then I started making a slow recovery, clawing my way back to some sort of fitness again, said Luke.

Im now doing great. Ive gone from having a cough most of the day to not having a cough at all. It is literally life transforming stuff.

The family had looked forward to travelling this year following Lukes recovery. Those plans are on hold while Luke shields, but he has maintained a positive outlook.

We have basically not been out the house since the middle of March, but we are lucky to live on the doorstep of lovely countryside where we dont see anybody, so we can go for walks, said Luke.

I think, really, until a vaccine comes along it may be a case of staying in the four walls and only venturing to places where we wont come into contact with anyone.

People with CF are resilient. On the one hand lockdown has been tough, but in a way we are more used to it already. We are used to staying away from anyone who might be ill, we are used to time away from family and friends when we are in hospital, we are used to being aware of bugs out there. In a way, it has come as a tough thing, but its not something most of us with CF havent experienced to some extent.

Shielding has given Luke the opportunity to focus his attention on a project close to his heart his book.

While he had always intended to write about his life and CF experiences, being on the transplant list inspired him to put pen to paper to ensure his children knew more about him should he not survive.

When I went on the transplant list I spent a year coming to terms with it. It is a terrifying thing, said Luke

You dont know if you will be waiting weeks, months or years. It could transform your life or end it. There is a very real chance you wont survive the operation or the initial four-week period afterwards. The idea of writing a book kept coming back to me.

Luke started writing in September 2018 and by the time he had the transplant he had written 10 of the 20 chapters. After spending last summer recovering, he started writing again in September 2019 and finished in March.

He hopes to release the book in September and has launched a crowdfunding campaign to fund the self-publishing costs of Coughing It All Up. In addition to raising awareness of CF, the book will raise funds for the Cystic Fibrosis Trust, with 20 per cent of royalties going to the charity as well as a lump sum if the crowdfunding campaign reaches its 8,000 target.

I wrote the book for my kids, so they would know something about my early life, but now it has taken on a life of its own, said Luke, 48.

It is not just a book about CF and my double lung transplant, I have tried to throw in as much non-CF material as possible. It is about what you can do in life despite having CF.

I have managed to achieve some exciting things. CF is a serious condition, it does impair and impact, but in a way dont let it rule you and despite it being there, carry on and do what you want to do anyway. You have to get up and grab on to life and go for it.

I always say I am so lucky. I have CF, but I have also managed to do all these amazing things. I have done so much, so how could I sit here and think I am not lucky?

Donate at https://www.crowdfunder.co.uk/coughing-it-all-up

Sammie Read, who lives near Stowmarket, has started a new and life-changing drug during her time shielding.

Before lockdown I was told there was a chance I might be offered a new drug, Trikafta. My consultant requested for me to be able to take the tests three weeks into lockdown and I was accepted, said Sammie.

Within six hours of starting I could feel my chest changing. Trikafta is an amazing drug. Previously my lung function was under 40 per cent and it is now at 60 per cent. I cant believe that in three weeks on Trikafta I am not coughing at night and my resting heart rate has dropped.

It is not a cure, but it has made a massive difference to my life.

Sammie, who lives with her husband Ewan and two dogs, said she had missed going to the gym, which she visits four times a week as exercise helps to keep her airways clear.

But like Luke, Sammie has ventured into the countryside during the months of shielding, discovering footpaths she did not know existed despite living in Mendlesham for 30 years.

She has remained positive throughout, but said it hard been hard not being able to visit her son when he moved into his new home after lockdown began.

The one thing you want to do is support your child, said Sammie.

I have been so lucky living where we are.

CF people are very appreciative of life and every day we have. When youre little youre told you wont make your teens but last year I had a ball for my 40th and raised just shy of 20,000 for the CF Trust. The trust has kept me here.

For more information about CF Week, go to http://www.cysticfibrosis.org.uk

Continued here:

CF is a serious condition but you have to get up and grab on to life - Bury Free Press

A potential Foreign Military Sales deal to Canada of an upgrade package for 36 Boeing CF-18 fighters has been approved by the U.S. State Department. The Royal Canadian Air Force (RCAF) is due to induct a new fighter type between 2025 and 2035, and its current Hornet fleet has been deemed unable to adequately meet Canadas NATO and NORAD commitments until then without significant investment.

As a first step, the Canadian Department of National Defence (DND) acquired 18 low-houred F/A-18A/Bs (and seven non-flying aircraft for spares) from the Royal Australian Air Force. The first of them arrived in Canada in February 2019 for modification to Canadian specifications. Under the DNDs C$360 million ($265 million) plan the former Australian aircraft are scheduled to achieve full operational capability in December 2022.

As a second step, the DND is to implement the Hornet Extension Project Phase 2 to equip two squadrons' worth of upgraded CF-18s. These aircraft are being modified with upgrades to sensors, weapons, survivability, security and mission support to improve combat capability, according to the DND HEP 2 document.

HEP 2now cleared by the U.S. and estimated at $863.2 millionincludes a range of systems and weapons that add significant enhancements to armament, communications, and sensor capability. A key element is the acquisition of the Raytheon APG-79(V)4 electronically-scanned radar, along with its associated wideband radome. Weaponry included in the potential sale comprises 50 AIM-9X Sidewinder Block II air-to-air missiles, as well as various associated training stores, and 20 AGM-154C Joint Stand-Off Weapons.

Other systems included in the package are new ARC-210 Gen 6 radios, new data transfer modules/units, joint mission planning systems, and upgrades to training systems. New triple ejector racks are on the shopping list, as are 30 Improved Tactical Air-Launched Decoys (ITALDs). Canada hopes to begin implementing this project in 2022, with initial deliveries scheduled for 2023. The program is expected to be completed by 2025/6, and its timing is aligned with the expected delivery schedule of the new fighter type.

That programdubbed Future Fighter Capability Project (FFCP)intends to procure 88 new fighters to completely replace the Hornet fleet. It was launched in late 2017 and was followed by the acquisition of the Australian F/A-18s as a stop-gap capability in place of a scrapped deal to buy 18 Boeing Super Hornets. A final request for proposal (RFP) was issued on July 23, 2019, leading to the Airbus/UK government team withdrawing the Typhoon from the competition. Dassault had withdrawn in November 2018, leaving FFCP as a three-horse race between the Saab Gripen E, Boeing F/A-18E/F Super Hornet Block III, and Lockheed Martin F-35A.

FFCP has been delayed again recently as a result of difficulties arising from the Covid-19 emergency. The initial deadline for responses to the RFP had earlier been extended from March 30 this year to June 30 in response to requests from industry but has now been further extended to July 31 in respect of Covid-related issues. A contract award for FFCP is slated for 2022.

See the original post:

Canada Cleared for Upgrade of 36 Boeing CF-18 Fighters - Aviation International News

Nitrogenous Fertilizer Market report has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

Nitrogenous fertilizer market is expected to reach grow at a growth rate of 4.80% in the forecast period of 2020 to 2027. Increasing awareness among farmers regarding soil nutrition will act as a driving factor for the nitrogenous fertilizer market in the forecast period of 2020- 2027.

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Get the PDF Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nitrogenous-fertilizer-market

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Nitrogenous Fertilizer. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Nitrogenous Fertilizer Market Country Level Analysis:

The countries covered in the Nitrogenous Fertilizer Market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Find More Competitor in TOC with Profile Overview Share Growth Analysis @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nitrogenous-fertilizer-market

Leading Nitrogenous Fertilizer manufacturers/companies operating at both regional and global levels:

Bunge Limited, Agrium, Yara, Nutrien Ltd, EuroChem Group, CF Industries Holdings, Inc., Sinofert, CVR Partners LP, Koch Industries and Potash Corp. of Saskatchewan Inc. among other domestic and global players.

Key factors influencing market growth:

Reasons for purchasing this Report from Data Bridge Market Research

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

If You Have Any Query, Ask Our Experts @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-nitrogenous-fertilizer-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact Us:

Data Bridge Market Research

Tel: +18883872818

Email: [emailprotected]

Read the original:

Nitrogenous Fertilizer Market Is Expected To Create New Opportunities By 2027 | CF Industries Holdings, Inc., Sinofert, CVR Partners LP - 3rd Watch...

Just a few short months ago, the Cystic Fibrosis (CF) community was making strides in their fight to have life-saving 'orphan' drugs approved in Canada.

Then COVID-19 hit, and their efforts were put aside as the government grappled with the pandemic.

Local resident, Beth Vanstone, mother of CF Warrior Madi Vanstone, spoke with BradfordToday earlier this week to discuss the challenges the CF community is now facing and the tremendous effort being made to have the government to approve orphan drugsin Canada, not only for CF patients, but for all Canadians with rare conditions and diseases.

What are orphan drugs? And why are they critical to so many Canadians?

Orphan drugs treat rare diseases. They tend to be hugelyexpensive,due to the lengthy research involved in development, and the small percentage of people needing them. There is no chance of mass-production or mass-consumption, to bring down the price.

Eighteen-year-old Madi is currently on the medication Kalydeco, another orphan drug,to treat her CF.

Madi was diagnosed with CF at nine months of age, and struggled throughout childhood with multiple hospitalizations due to her illness, often missingschool.

Six years ago, when Kalydeco was released, Madi was able to take the drug as part of a drug trial - and the Vanstones launched their battle with theOntario government, to have themedication Kalydeco covered by OHIP. Without coverage, the cost to the Vanstones - even with private insurance and a discount from the pharmaceutical company - would have come to approximately $60,000 per year.

The government did approve coverage of the medication, which she is still on today. Kalydeco has substantially improved the quality of her life.

But their fight isnt over. Madi and her mom have been working tirelessly to help other CF patients and other Canadians with rare diseases gain access to the orphan drugs they require.

There are currently three new CF modulators (drugs) from the pharmaceutical company Vertex -Orkambi, Symdeco and Trikafta -with very little access to Canadians.

Since the COVID-19 pandemic, CF Canada has reached out to the government and Vertex Pharmaceuticals to allow CF patients access to all current and future CF modulators.

In a letter to the federal government,CEO of CF Canada Kelly Glover noted that the pharmaceutical company Vertex had recently made an offer to the pan-Canadian Pharmaceutical Alliance (pCPA), and urged the government to negotiate on the offer right away.

Cystic fibrosis is a fatal disease," Glover wrote. "Similar to COVID-19 it affects primarily the respiratory system. Similar to COVID-19, it kills people. Unlike COVID-19 its much more efficient, just slower. Eighty five percent of people with CF will die from respiratory failure, but CF will ultimately kill them all, as compared to only about 1-2% for COVID. But instead of dying in weeks, CF slowly deprives everyone with CF of quality of life. Our 4,300 patients spent a total 26,500 days in hospital in 2018. Thats 72 years! Seventy-two years worth of hospital resources that could be better spent taking care of people with COVID-19.

But the pCPA has indicated that it is not negotiating a deal for two of the three CF modulators, Orkambi and Symdeco, but isonly considering negotiating for Trikafta, once it is approved by Health Canada. Currently Trikafta can only be made available in compassionate cases if the patient meets specific criteria.

Our community is so vulnerable, having underlying respiratory issues already, said Beth, worried about the additional impact of COVID-19.

Everyday our people have to be six feet a part, everyday if theres somebody sick we cant go to them. Our kids cant touch things because they can get sick and end up in the hospital, she said.This is our life. Everyones getting a little test of what its like to have CF.

A response from the pCPA Governing Council stated, The pan-Canadian Pharmaceutical Alliance (pCPA) recognizes that this is a challenging time, especially for cystic fibrosis patients during the COVID-19 pandemic.

The Council noted that they have held numerous meetings with Vertex, hoping to reach an agreement to improve access to drug treatments for cystic fibrosis patients. The alliance continues to encourage Vertex to submit Trikafta to Health Canada and if approved, to then submit it to Canadian Agency for Drugs and Technology in Health (CADTH) or lInstitut national dexcellence en sant et en services sociaux (INESSS) for a Health Technology Assessment (HTA) review, the response stated.

The cPCA declined to providedetails of the discussionswith Vertex due to confidentiality reasons, but noted, the pCPA continues to engage with Vertex with the goal of bringing new cystic fibrosis medications to the Canadian market."

Beth and the rest of the CF community point to a disparity: governments are providing unlimited funding forCOVID-19 patient care, but there is alack of funding of treatment for CF patients who suffer breathing issues everyday.

We will spend whatever, and shut down our country, to save people from COVID, said Beth, yet it's too expensive to pay for the medications for CF patientsthat could ease the suffering, and reduce hospitalizations.

You cant help but take it a little personal, she said. Its really frustrating that the government doesnt seem to care.

She also worries that,with the new rules for the Patented Medicine Prices Review Board (PMPRB) set to come into effect this July, it will be even more difficult for companies like Vertex to market in Canada, due to the high price of orphan drugs.

The new rules and regulations for lowering the cost of medications for patients across Canada are supposed to take effect in July 2020. The PMPRB has said itwill be publishing an updated version of its draft pricing Guidelines for public consultation in the coming weeks.

This document is responsive to stakeholder feedback, including concerns from patient advocacy groups about the impact of the pending changes on access to promising new drug therapies, said Communications Advisor for the PMPRB, Jeff Wright.

Beth Vanstone is currently working with the group CF Get Loud, which has joined forces with CORD (Canadian Organization for Rare Disease) to oppose the PMPRB changes.

They (CORD) represent the rare disease community, and of course innovative therapies are so expensive for them as well, so they are going to be cut off from medications as well, she explained.

Simcoe-Grey MP Terry Dowdall has been working with the Vanstones and the CF community, to gettheir voices heard. He recently raised his concerns in the House of Commons, in an effort to have Patty Hajdu rescind the changes to the PMPRB.

"You are seeing how money can become available for certain issues," he explained, referring to the government spending on COVID-19, "Health is number one, we really need to take care of Canadians here in our homeland."

He belives the longterm costs of keeping CF patients in hospitals and on disability, far outweigh the costs of their needed medications.

"We're going to keep pushing it and Ihope one day its not an issue," he said. "I'm hoping the government does the right thing."

We are pushing that the changes be rescinded or an implementation date be changed to 2022 where they are apparently coming up with a rare disease strategy, Beth said.When they have a path set up for rare diseases in 2022, implement the changes at that time so orphan drugs can stream off on their own.

She is hoping that way, future drugs for rare diseases will not have to go through the same restrictive criteria.

What the PMPRB is doing right now is deciding for all Canadians what medications they will have access to, and its a very small percentage of whats available to everyone else in the world, Vanstone said. And instead of improving negotiations with pharmaceutical companies,theyre taking that opportunity right out, she said.

Wright, responding for PMPRB, stated thatIf any business decisions affecting Canada are being contemplated by pharmaceutical companies as a result of the draft Guidelines, it would be premature to take them until such time as the document is finalized.

He added that manufacturers don't need the PMPRBs prior approval of their price in order to launch drugs in Canada.

Beth is worried that, with all the emphasis on cost-savings,Canadians are not seeing the 'bigger picture' andthe implications of the PMPRB, especially for orphan drugs.

These drugs are available everywhere else. Noother country is doing something like this, she fumed. Its a war against big pharma, and patients are the casualties. Its heartbreaking."

The Vanstones and the rest of the CF community feel like they are on the wrong side in a losing battle.

I really have always thought people came first in Canada, until getting involved in this kind of scene and seeing that its not really true, Beth said.

As for the PMPRB, I think it was a really poorly thought-out plan, and now theyve dug their heels in, she said, noting that the plan may be a good idea for general medications for things like a cold, but not for those whoneed innovative life-saving medicines for rare diseases.

On June 3, the CF Get Loud community will be hosting a virtual Town Hall for patient advocacy, calling on Federal Health Minister of Canada Patty Hajdu and other MPs to rescind the changes in the PMPRB, so that the drugs can be submitted to help save patients lives.

Bethencourages anyoneinterested in learning more about the future of Canadas health care system in relation to new and innovative medications, to tune in.

Its not just going to be about CF," she said. "Its about our (health care) system and whats happening.

Link:

Local mother, daughter 'getting loud' for CF and the need for lifesaving medication - BradfordToday

A former Nationals leadoff man and fan favorite has reportedly come to terms with the possibility of his baseball career reaching its conclusion.

Centerfielder Denard Span played in Washington from 2013-15, hitting .292 with 62 stolen bases and 207 runs scored as the teams primary hitter at the top of the lineup. Following stints with the San Francisco Giants, Tampa Bay Rays and Seattle Mariners over the next three seasons, Span has spent the last year and a half as a free agent.

I havent announced it, officially, but maybe this is it, Span told the Minnesota Star Tribune in a story published Saturday. I didnt play last yearnot because of an absence of contact from teams. The offers that came my way; they didnt seem like fair value for my services.

I spent this past offseason getting in shape, getting ready to play in 2020, and there were two or three minor league offers. I wasnt opposed to starting in the minors, but these didnt seem right as far as having a chance to move up to the big club if I was doing well in Triple-A.

CLICK HERE TO SUBSCRIBE TO THE NATIONALS TALK PODCAST

Span, a former first-round pick, started his career with the Minnesota Twins in 2008. He played five years in Minneapolis before traded to the Nationals just after the 2012 season. Washington was in desperate need of both an everyday centerfielder and a leadoff man, and Span checked off both boxes.

As a sparkplug that ignited the Nationals offense, Span quickly earned the appreciation of fans in D.C. His best season came in 2014, when he led the NLwith 184 hits and placed 19th in MVP voting. When the Nationals clinched a playoff berth last September, Span commented on the teams Instagram page to say his time in D.C. was the best 3 years of my career.

A day after he signed a free-agent contract with the Giants over the 2015-16 offseason, the Nationals moved on by acquiring Ben Revere from the Toronto Blue Jays in exchange for reliever Drew Storen. Revere kick-started another round of musical chairs at the center field position in D.C. until Victor Robles took over the job full-time last season.

Span admitted to the Star Tribune that while hed be open to returning to the majors, there likely wont be a situation that will entice him enough to do so.

I know that if the season ever would get started, he said, I still would have the ability to help a team. But 36-year-old outfielders who havent played in two yearsnot happening.

Im very satisfied pouring my life into our family, to [my wife] Anne, a wonderful person, and our two boys.

Stay connected to the Capitals and Wizards with the MyTeams app.Click hereto download for comprehensive coverage of your teams.

MORE NATIONALS NEWS:

See more here:

Former Nats CF Denard Span mulling retirement: 'Maybe this is it' - NBCSports.com